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Nervous systemr factor of activated T cells (NFAT) family (NFATC1, NFATC2, NFATC3, and NFATC4)
are Ca2+-regulated transcription factors that regulate several processes in vertebrates, including the
development and function of the immune, cardiovascular, musculoskeletal, and nervous systems. Here we
describe the structures and alternative splicing of the human and mouse NFAT genes, including novel splice
variants for NFATC1, NFATC2, NFATC3, and NFATC4, and show the expression of different NFAT mRNAs in
various mouse and human tissues and brain regions by RT-PCR. Our results show that alternatively spliced
NFAT mRNAs are expressed differentially and could contribute to the diversity of functions of the NFAT
proteins. Since NFAT family members are Ca2+-regulated and have critical roles in neuronal gene
transcription in response to electrical activity, we describe the expression of NFATC1, NFATC2, NFATC3, and
NFATC4 mRNAs in the adult mouse brain and in the adult human hippocampus using in situ hybridization
and show that all NFAT mRNAs are expressed in the neurons of the mouse brain with speciﬁc patterns for
each NFAT.
© 2008 Elsevier Inc. Open access under CC BY license.Nuclear factor of activated T cells (NFAT) is a family of transcription
factors evolutionarily related to Rel/NF-κB [1]. The family consists of the
Ca2+-regulated members NFATC1 (NFATc, NFAT2), NFATC2 (NFATp,
NFAT1), NFATC3 (NFATx, NFAT4), and NFATC4 (NFAT3) and osmotic
tension-regulated NFAT5. The approved human symbols for the NFAT
familymembers areNFATC1, NFATC2,NFATC3,NFATC4 andNFATC5 and
the approved mouse symbols are Nfatc1, Nfatc2, Nfatc3, Nfatc4 and
Nfatc5. The Ca2+-regulated NFAT proteins consist of two conserved
domains—a regulatory domain in the N-terminus and a Rel homology
domain (RHD) in the C-terminus [2]. The regulatory domain consists of
two conserved binding sites for the protein phosphatase calcineurin
(CaN) [3,4], an extended serine-rich region, and a nuclear localization
signal (NLS) [5]. The Rel homology domain binds DNA and interacts
with partner proteins (also referred as NFATn) to transactivate gene
transcription. The partner transcription factors include AP-1 (FOS or
JUN) [6], GATA4 [7], and MEF2 [8], for example. The N- and C-terminal
ends of each NFAT family protein are unique and contain transcription
activation domains (TADs) [9].in the GenBank Data Libraries
n NFATC1 transcript types);
ypes); EU887605- EU887625
55 (Human NFATC4 transcript
types); EU887581- EU887604
31 (Mouse Nfatc3 transcript
types).
 license.The NFAT proteins exist in at least two alternative conformations—
one inwhich the NLS is exposed and the nuclear export signal (NES) is
masked or vice versa. This is achieved by dephosphorylation or
phosphorylation, respectively, of serines in the regulatory domain
[10]. NFATs are dephosphorylated by CaN [11] and phosphorylated by
various kinases [10] such as casein kinase 1 (CSNK1A1), glycogen
synthase kinase 3 (GSK3A or GSK3B), p38 MAP kinase (MAPK14), and
JUN N-terminal kinase (MAPK8), [12–16]. Exposure of the NLS leads to
rapid import of the NFAT proteins into the nucleus, where they bind to
DNA and regulate target gene expression [17], whereas phosphoryla-
tion causes rapid relocalization out of the nucleus, terminating NFAT-
dependent transcription regulation [18].
NFAT proteins regulate gene transcription in various developing
and adult tissues. For example, their roles in the immune system [2],
cardiovascular system [2,19], skeletal muscle [20], and nervous system
[21,22] have been described. Accordingly, NFAT genes are expressed in
almost all tissues. However, the expression levels and patterns for
each NFAT are rather distinct [17,23]. All of the NFAT genes except
NFATC4 are strongly expressed in the immune system, in the thymus,
spleen, and peripheral blood lymphocytes [23–28], but are also
expressed at lower levels in other tissues.NFATC1 has been detected in
the cardiovascular and digestive systems, for example [26,29,30], and
NFATC2 expression has been detected in the testis, pancreas, placenta,
and brain–in the hypothalamus, hippocampus, cerebellum, olfactory
bulb, and frontal cortex [23,24,31–33]. In addition to the immune
system, NFATC3 is expressed in the skeletal and smooth muscle,
kidney, and lung and in the brain, where it has been shown to be
expressed in the hypothalamus and striatum [26,28,31,34,35]. NFATC4
is more evenly expressed than the other NFATgenes and its expression
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Table 1
Usage of alternative 5′ and 3′ exons and alternative splicing of human and mouse NFAT
genes
Gene Human Mouse
NFATC1 5′ exons IA [24] [41]
IB [29] [42]
3′ exons VIII [24] [42]
X [29] [41]
Alternative splicing IXL [45] +
IXS [29] [41]
ΔIX + ND
NFATC2 5′ exons IA + +
IB [43] [44]
3′ exons III ND +
VIIA ND [33]
X [43] [43]
Alternative splicing IIL [43] [43]
IIS + +
ΔII ND +
XA [43] [43]
NFATC3 5′ exons IAL + [32]
IB [23] [46]
IC + ND
ID + ND
IE + ND
IF + ND
3′ exons IV ND +
IX [26] ND
X [26] [32]
Alternative splicing IAS + ND
XA [23] [46]
XB [26] ND
NFATC4 5′ exons IA + ND
IB + ND
IC + ND
ID [23] [1]
IE + ND
IV + ND
VI + +
3′ exon X [23] [1]
Alternative splicing IEi + ND
VIi ND +
IXL [23] [1]
IXS + ND
IXi + +
+, novel transcript identiﬁed in this study; ND, not detected; references indicate studies
describing the respective transcript variant.
281H. Vihma et al. / Genomics 92 (2008) 279–291has been detected in the placenta, lung, kidney, adipose tissue, cardiac
muscle, testis, ovary, digestive system, and spinal cord and, at lower
levels, in the brain—in the hippocampus, cerebellum, olfactory bulb,
and various hypothalamic nuclei [19,21,23,34,36–40].
Despite this information, the expression of different NFAT isoforms
generated by splicing or usage of alternative 5′ and 3′ exons has not
been studied. Therefore, here we describe the structures of the human
and mouse NFATC1, NFATC2, NFATC3, and NFATC4 genes and analyze
their alternative splicing and coding potentials. Furthermore, we have
studied the expression of different NFATC1, NFATC2, NFATC3, and
NFATC4mRNA splice variants in various mouse and human tissues and
brain regions by RT-PCR and describe here the expression of the NFAT
mRNAs in the adult mouse brain and in the adult human hippocampus
using in situ hybridization.
Results
The structure of the human and mouse NFAT genes
The exon/intron structures of the human and mouse NFAT genes
were characterized and the alternative splicing patterns of each NFAT
gene in both human and mouse were analyzed using bioinformatics
and RT-PCR. For each NFAT a search for mRNA sequences and
expressed sequence tags (ESTs) was performed. RT-PCR analyses
were used for the characterization of the expression patterns of the
alternative transcripts in human and mouse.
The lengths of the four human NFAT genes vary from 10kb for
NFATC4 up to 170kb for NFATC2 (Fig. 1). The NFAT genes are conserved
in their central regions but are less similar in the 5′ and 3′ parts. The
identity on the nucleotide level and the identity and strong similarity
of the amino acids on the protein level among themost conserved part
of the genes, encoded by exons V–VII, is ∼ 80%. Although these exons
are strongly similar, other exons are not so conserved. The identity
among the full-length NFAT coding regions is ∼ 50% on the nucleotide
level and the amino acid identity or strong similarity in sum of the
human NFAT proteins is ∼ 56%.
There are several alternative transcripts for the NFAT genes, which
are generated by usage of alternative 5′ and 3′ exons and alternative
splicing. According to our data, human and mouse NFATC1 and
NFATC2, and mouse Nfatc3 and Nfatc4, have two alternative 5′ exons.
In human we detected six alternative 5′ exons for NFATC3 and seven
alternative 5′ exons for NFATC4. Our results also showed that in both
human and mouse, NFATC1 and NFATC3 have two alternative 3′ exons
and NFATC4 has one 3′ exon. For NFATC2 we detected one 3′ exon in
human but three alternative 3′ exons in mouse. Due to these
differences, the amino acid sequences within the C- and N-termini
of different NFAT protein isoforms are distinct (Supplementary Figs. 1
and 2). In this study the alternative transcripts and protein isoforms
have been given names according to the alternative exons used in the
respective mRNAs (Fig. 1).
Alternative splicing and expression of NFATC1 in human and mouse
For both human and mouse NFATC1, there are two alternative 5′
exons, exons IA and IB, and two alternative 3′ exons, exons VIII and X
(Fig. 1; Table 1). Also, in both human and mouse exon IX has two
alternative splice variants, designated here IXL and IXS, which are
generated by the usage of alternative splice donor sites. In addition,
we detected a novel splice variant for human NFATC1 lacking exon IX,
indicated here as ΔIX. In human, exon IA encodes 42 amino acids (aa).Fig. 1. Structure and alternative transcripts of human NFAT genes. The structural organization
and mRNA sequence data using bioinformatics and RT-PCR. Exons are shown as boxes and in
coding part of the exon. Protein coding sequences of the mRNAs are shown as ﬁlled boxes and
Exon numbers are shown in roman characters. Asterisks mark rarely used exons and rarely
DBD, DNA binding domain; RHD, Rel homology domain; Cn, calcineurin A.Exon IB, located downstream from exon IA, encodes 29 aa. Transcripts
that have the polyadenylation signal in exon VIII (VIII3′UTR) encode 63
aa from exon VIII, whereas transcripts containing exon X as the 3′ exon
encode a C-terminal region that includes 44 aa identical to the exon
VIII3′UTR isoforms in the region encoded by exon VIII, but contain an
additional 245 aa or 127 aa, in the case of IXL or IXS usage,
respectively. If exon IX is skipped the corresponding protein isoform
lacks the 230 aa encoded by exon IXL but contains 15 C-terminal
amino acids identical to the C-terminus of the exon IXL-comprising
isoform. Altogether, according to our data, the possible transcript
types of NFATC1 in human are: (1) NFATC1-IA/IB-IXL, containing 5′
exon IA or IB, exon IXL, and 3′ exon X, having a protein coding region of
2829bp when exon IA is used or 2790bp when exon IB is used; (2)
NFATC1-IA/IB-ΔIX, containing 5′ exon IA or IB, no exon IX, and 3′
exon X, having a protein coding region of 2139bp when exon IA is used
or 2100bp when exon IB is used; (3) NFATC1-IA/IB-IXS, containing 5′
exon IA or IB, IXS, and 3′ exon X; exon IXS changes the open reading
frame, introducing a stop codon in exon X that is 44bp upstream of the
stop codon in type 1 and type 2 transcripts; the protein coding regionsof human NFATC1, NFATC2, NFATC3, and NFATC4was determined by analyzing genomic
trons are shown as lines. The numbers above the exons indicate the size of the protein
open boxes indicate UTRs of the mRNAs. Numbers below the introns indicate their size.
transcribed mRNA variants. NES, nuclear export signal; NLS, nuclear localization signal;
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when exon IB is used; and (4) NFATC1-IA/IB-VIII, containing 5′ exon IA
or IB and 3′ exon VIII; the coding region of exon VIII in type 4
transcripts is 56bp longer than in type 1, 2, and 3 transcripts; the
protein coding regions are 2148bp when exon IA is used or 2109bp
when exon IB is used (Fig. 1 and Supplementary Table 1). A human EST
sequence corresponding to the NFATC1 transcript lacking exon II is
present in the databases; however, we did not detect it with RT-PCR
and there are no references in the literature to conﬁrm the generation
of this transcript. According to our data Nfatc1 transcripts for mouse
are the same as in human, except for differences in the lengths of
exons II, III, IXL, and IXS and in the length of the protein coding region
of exon IB (data not shown).
In mouse, Nfatc1 transcripts containing exon IA or exon IB were
both predominantly expressed in the lung, thymus, and spleen (Fig. 2).
Both alternative 3′ exon transcripts were detected in all tissues
analyzed, with the levels being highest in the lung, thymus, and
spleen. Exon IXS was more abundantly used than exon IXL in 3′ exon
X-containing transcripts. In the adult mouse brain and duringFig. 2. Semiquantitative analysis of Nfatc1, Nfatc2, Nfatc3, Nfatc4, and control Hprt mRNA ex
developmental time points, and in various mouse tissues.postnatal development of the brain the expression levels of transcripts
containing exon IA or exon IB were similarly low (Fig. 2). In embryonic
mouse brain, only Nfatc1 transcripts comprising exon IA were
expressed. In all the brain regions tested the expression levels of
both of the 3′ exon transcripts were lower compared to the levels of
respective mRNAs in the thymus, spleen, or lung (Fig. 2).
In human, NFATC1 transcripts comprising exon IA were expressed
more widely than transcripts comprising exon IB (Fig. 3). Both 5′ exon
transcripts were highly expressed in the thymus and muscle. In
addition, exon IA transcripts were expressed at high levels in the
colon, small intestine, stomach, heart, uterus, testis, and thyroid and
were detected also in other tissues. Exon IB mRNAs were highly
expressed also in the fetal brain, cerebellum, and placenta and were
undetectable in the stomach, uterus, liver, fetal liver, pancreas, salivary
gland, trachea, and adrenal gland. Both 3′ exon transcripts were
expressed in all the tissues analyzed, with highest levels observed in
the testis, thymus, and muscle. Transcripts containing the 3′ exon X
and exon IXS were expressed more predominantly than transcripts
containing exon IXL or those in which exon IX was skipped. mRNAspression by RT-PCR in different mouse brain regions, in mouse brain at the indicated
Fig. 3. Semiquantitative analysis of NFATC1, NFATC2, NFATC3, NFATC4, and controls GAPDH and HPRT mRNA expression by RT-PCR in various human tissues and brain regions.
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in the small intestine, heart, liver, pancreas, salivary gland, brain, and
fetal brain. Transcripts lacking exon IX or containing exon IXS were
both highly and at comparable levels expressed in the thymus,
thyroid, and muscle. The analysis of the expression of NFATC1
transcripts in various human brain regions showed that transcripts
comprising exon IA or exon IB were present in all regions tested, with
highest levels in the corpus callosum (Fig. 3). Exon IA transcripts were
expressed at relatively higher levels also in the olfactory bulb. Both of
the alternative 3′ exons were also expressed in all of the regions
analyzed, with the highest levels in the corpus callosum. The relativeratio of transcripts containing IXL or IXS was similar in most of the
regions analyzed, except in the olfactory bulb, cerebral cortex, corpus
mammilare,medulla, pons, and substantia nigra, where the expression
levels of transcripts containing IXL were slightly higher. Transcripts
lacking exon IX were not detected in the brain (Fig. 3).
Alternative splicing and expression of NFATC2 in human and mouse
Both human and mouse NFATC2 contain two alternative 5′ exons,
IA and IB, whereas only exon IB has been previously described (Fig. 1
and [41]). There is one 3′ exon in human, exon X, and three 3′ exons in
284 H. Vihma et al. / Genomics 92 (2008) 279–291mouse, exons III, VIIa, and X (Table 1). Due to the usage of alternative
splice acceptor sites exon II has two splice variants—IIL and IIS. Exon
IIL is 1030 or 1036bp in length in human or mouse, respectively, and
exon IIS is 516bp in both organisms. The shorter splice variant of exon
II has not been described before. In mouse, exons IIS and IIL are both
used and transcripts without exon II are also expressed, whereas in
human the transcripts containing IIL are predominant and the usage
of exon IIS or skipping of exon II is barely detectable. In both human
and mouse exon IA encodes 23 aa and exon IB encodes 43 aa.
Regardless of the 5′ exon, the translation start codon is positioned in
exon II when exon IIS is used in transcripts. This leads to N-terminally
truncated isoforms that are 199 and 201 aa (IA) or 219 and 221 aa (IB)
shorter than the isoforms encoded by transcripts containing exon IIL
in human and mouse, respectively. In both human and mouse NFATC2
there is an additional exon compared to NFATC1, located upstream of
exon X, named Xa here, that is either spliced in the mRNA or skipped.
Usage of exon Xa leads to a translation stop codon in exon Xa. If exon
Xa is not used then the translation stop codon is in exon X. This
generates unique C-terminal sequences of 17 or 13 aa, for the
respective NFATC2 protein isoforms. Taken together, our results
showed that the possible transcript types of NFATC2 in human are:
(1) NFATC2-IA/IB-IIL-Xa, containing 5′ exon IA or IB, exon IIL, exon Xa,
and 3′ exon X, having a protein coding region of 2703bp when exon IA
is used or 2763bp when exon IB is used; (2) NFATC2-IA/IB-IIS-Xa,
containing 5′ exon IA or IB, exon IIS, exon Xa, and 3′ exon X, having a
protein coding region of 2106bp with either exon IA or exon IB; (3)
NFATC2-IA/IB-IIL-ΔXa, containing 5′ exon IA or IB, exon IIL, and 3′
exon X and lacking exon Xa, having a protein coding region of 2715bp
when exon IA is used or 2775bp when exon IB is used; (4) NFATC2-IA/
IB-IIS-ΔXa, containing 5′ exon IA or IB, exon IIS, and 3′ exon X and
lacking exon Xa, having a protein coding region of 2118bp with either
exon IA or exon IB (Supplementary Table 1).
There are several differences in the mouse Nfatc2 transcripts
compared to the human ones in addition to the length of exon II. First,
there are three alternative 3′ exons in mouse: exon III, exon VIIa, and
exon X. The proteins encoded by transcripts using exon III or VIIa as 3′
exon lack the whole or a part of the Rel homology domain,
respectively. Second, in mouse we detected Nfatc2 transcripts lacking
exon II (ΔII). Of note, according to themouse ESTandmRNAdata in the
NCBI databases there are transcripts in which exon V is used as the 3′
exon and transcripts with an alternative 5′ exon between exons III and
IV. However, we did not detect these transcripts with PCR and there
are no references to these transcripts in the literature.
Mouse Nfatc2 transcripts containing exon IA, including transcripts
with the mouse-speciﬁc 3′ exon III and transcripts with the 3′ exon
VIIa, were all highly expressed in the brain, where the expression
levels increased during postnatal development. In the adult mouse
brain high levels were observed in the colliculi, cerebellum, medulla,
olfactory bulb, and striatum (Fig. 2). Exon VIIa transcripts were highly
expressed also in the heart and muscle. The levels of transcripts with
exon X as the 3′ exon, either containing or lacking exon Xa, were
relatively higher in the heart, testis, thymus, spleen, and brain, where
they were more abundant in the colliculi, cerebellum, medulla,
olfactory bulb, and striatum. Transcripts including exon IB predomi-
nantly contained exon IIL and were more broadly expressed, with
relatively higher expression levels in the heart, thymus, and spleen.
Transcripts containing exons IB and III3′UTR showed the highest
expression levels in the heart and thymus and were very weakly
expressed in the brain (Fig. 2).
In human, NFATC2 transcripts including exon IA spliced to exon IIL
were highly expressed in the stomach, uterus, thymus, placenta,
trachea, and thyroid (Fig. 3). Transcripts containing exons IB and IIL
were expressed highly in the small intestine, heart, testis, prostate,
thymus, placenta, and thyroid. Transcripts containing IIS were hardly
detectable (data not shown). Transcripts of NFATC2 containing the 3′
exon X and either comprising or lacking exon Xa (ΔXa) were bothpresent in all of the tissues analyzed, with exon Xa-containing
transcripts being expressed at slightly higher levels. In the brain
NFATC2 was widely expressed. The expression levels were highest in
the caudate putamen for exon IA and the olfactory bulb and corpus
callosum for exon IB transcripts. Similar levels of exon Xa and ΔXa
transcripts were expressed in almost all regions of the human brain
except in the olfactory bulb, colliculi, nucleus ruber, corpus callosum,
and caudate nucleus, where exon Xa transcripts were predominant
(Fig. 3).
Alternative splicing and expression of NFATC3 in human and mouse
The human NFATC3 contains six 5′ exons located within ∼ 4500bp
in the genome (Fig. 1), whereas in mouse there are only two
alternative 5′ exons in Nfatc3. The human exon IB has been described
before [23]. However, exons IA, IC, ID, IE, and IF are ﬁrst described in
this study (Table 1). Exon IB in human is homologous to exon IB in
mouse and encodes 34 N-terminal amino acids of the respective
proteins. Mouse 5′ exon IA is not homologous to human exon IA and
encodes a unique N-terminus of 26 aa. In human, exon IB is the only 5′
exon that is a protein-coding exon. Exons IA, IC, ID, IE, and IF all lack an
in-frame translation start codon and translation of NFATC3 transcripts
containing these exons could start from the ATG located in exon IV.
Thus, proteins encoded by these transcripts would not contain the 485
N-terminal amino acids present in NFATC3 isoforms translated from
transcripts including exon IB. Exon IA in human contains two
alternative splice donor sites and the respective splice variants are
named here IAL and IAS. There are two alternative 3′ exons in NFATC3
genes: exons IX and X in human and exons IV and X in mouse.
Transcripts in which exon IX is used as the 3′ exon encode proteins
with 9 unique C-terminal amino acids that are not present in the
proteins encoded by exon X-containing transcripts. Like in human
NFATC2 there is an alternative exon located between exon IX and exon
X, designated here Xa, in both human and in mouse NFATC3 genes. If
exon Xa is used in the transcripts a stop codon is introduced.
Therefore, different C-terminal sequences of 32 or 39 aa are encoded
by exon X3′UTR transcripts depending on the usage or skipping,
respectively, of exon Xa. Altogether, according to our data, the possible
transcript types of NFATC3 in human are: (1) NFATC3-IB-Xa, containing
5′ exon IB, exon Xa, and 3′ exon X, having a protein coding region of
3204bp; (2) NFATC3-IB-ΔXa, containing 5′ exon IB and 3′ exon X and
lacking exon Xa, having a protein coding region of 3225bp; (3)
NFATC3-IB-IX, containing 5′ exon IB and exon IX as the 3′ exon, having
a protein coding region of 3135bp; (4) NFATC3-IAL/IAS/IC/ID/IE/IF-Xa,
containing 5′ exon IAL or IAS or IC or ID or IE or IF, exon Xa, and 3′ exon
X, having a protein coding region of 1767bp; (5) NFATC3-IAL/IAS/IC/ID/
IE/IF-ΔXa, containing 5′ exon IAL or IAS or IC or ID or IE or IF and 3′
exon X and lacking exon Xa, having a protein coding region of 1788bp;
and (6) NFATC3-IAL/IAS/IC/ID/IE/IF-IX, containing 5′ exon IAL or IAS or
IC or ID or IE or IF and exon IX as the 3′ exon, having a protein coding
region of 1698bp (Supplementary Table 1). Masuda et al. have
described a human NFATC3 transcript containing an additional exon
upstream of exon X and downstream of exon Xa [26]. However, we
were not able to detect this transcript in any of the tissues analyzed in
this study.
In mouse, the expression of Nfatc3 transcripts containing exon IB
was detected in all tissues analyzed, with relatively higher levels in the
testis, lung, thymus, and spleen (Fig. 2). Exon IA transcripts were
barely detectable only in the testis and thymus (data not shown).
Nfatc3 transcripts containing the mouse-speciﬁc 3′ exon IV were
expressed at moderate levels in the thymus and spleen. However, with
the exception of muscle, low levels of this transcript were seen in all
the tissues analyzed. Transcripts containing the 3′ exon X were also
observed in all the tissues analyzed, with higher levels in the testis,
lung, thymus, and spleen. In the mouse brain exon IB transcripts were
expressed in all the regions analyzed (Fig. 2). Higher levels were seen
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levels of Nfatc3 transcripts containing exon IB remained unchanged
from embryonic day 13 (E13) up to adult, the developmental period
studied here. Transcripts with 3′ exon X were expressed in all brain
regions analyzed with, ΔXa transcripts being the predominant mRNAs
(Fig. 2).
In human, NFATC3 transcripts comprising exon IA or IB were more
widely expressed than exon IC, ID, IE, or IF transcripts (Fig. 3). Both IA
and IB transcripts were expressed at relatively higher levels in the
testis, fetal liver, thymus, and muscle. In addition, exon IB was highly
expressed in the prostate, placenta, thyroid, and cerebellum. IAL-
containing transcripts were expressed at higher levels than IAS-
containing transcripts. Transcripts containing exon IC were highly
expressed in the testis. Transcripts containing exon ID had high
expression in the testis, prostate, and thymus and lower expression in
the kidney, liver, fetal liver, trachea, thyroid, and muscle. Exon IE was
most strongly expressed in the testis and exon IF in the thymus. All the
NFATC3 3′ exon transcript variants were expressed in all the tissues
analyzed, with higher levels detected in the testis, fetal liver, prostate,
thymus, and placenta. In the heart and muscle, transcripts containing
exon Xa were expressed at slightly higher levels than transcripts
lacking exon Xa. In the human brain, transcripts comprising exons IA
and IB were expressed in all the regions analyzed, whereas exon IC
transcripts were expressed only in some regions, with relatively
higher levels in the cerebellum (Fig. 3). Exon ID transcripts were not
detected in the human brain. Exon IE was relatively more expressed in
the substantia nigra, optic nerve, and epiphysis and exon IF in the
epiphysis. Expression levels of both of the alternative 3′ exons were
similar in all the regions analyzed. Compared to the other brain
regions exon IX transcripts were present at slightly higher levels in the
olfactory bulb, cerebral cortex, cerebellum, and corpus callosum.
Transcripts containing exon Xawere mostly expressed at higher levels
than transcripts lacking exon Xa (Fig. 3).
Alternative splicing and expression of NFATC4 in human and mouse
Before our study, only one exon, named here exon ID, had been
described as a 5′ exon in human NFATC4 [23]. Our data show that
human NFATC4 has ﬁve 5′ exons within ∼ 2.5kb of the most upstream
part of the gene, named here IA, IB, IC, ID, and IE. In addition, 5′-
extended exons IV and VI are also used as 5′ exons (Fig. 1 and Table 1).
For mouse Nfatc4we identiﬁed two 5′ exons: the previously described
5′ exon, named exon I here, which is homologous to the human exon
ID [26], and the 5′-extended exon VI, which has not been described
before. With the usage of the 5′-extended exon VI in mouse, exclusion
and retention of the intron between exons VI and VII were detected.
Human exon ID and mouse exon I encode 33 aa. The human exon ID is
in addition used as an internal exon: 129bp of its 3′ part are always
inserted as the second exon in the transcripts starting upstream of
exon ID. This is due to a cryptic splice acceptor site inside exon ID.
Human NFATC4 transcripts that use the 5′ exon IA, IB, or IC encode
proteins with an additional 63, 13, or 32 aa, respectively, in their N-
termini compared to the protein encoded by the transcripts contain-
ing exon ID as the 5′ exon. If exon IEi (retention of intron between
exons IE and II), exon IV, or exon VI is used as the 5′ exon, the
corresponding human NFATC4 transcripts encode protein isoforms
that are 70, 465, or 711 aa, respectively, shorter in their N-terminus
compared to the protein encoded by the transcripts containing exon
ID as the 5′ exon. Exon X is used as the 3′ exon in all mouse and human
NFATC4mRNAs (Fig. 1). In human, there are two splice variants of exon
IX, named here IXL and IXS, due to the usage of alternative splice
donor sites. In addition, retention of the intron between exons IX and
X leads to transcript variants indicated by IXi here. If exon IXS is used,
the respective protein isoforms lack 108 aa in the C-terminal region
compared to protein isoforms encoded by exon IXL-containing
transcripts. IXi usage leads to protein isoforms with 20 uniqueamino acids in the C-terminus. In mouse, only exons IXL and IXi are
used. Taken together, our results showed that the possible transcript
types of NFATC4 in human are: (1) NFATC4-IA-IXL, containing 5′ exon
IA, exon IXL, and 3′ exon X, having a protein coding region of 2895bp;
(2) NFATC4-IA-IXS, containing 5′ exon IA, exon IXS, and 3′ exon X,
having a protein coding region of 2571bp; (3) NFATC4-IA-IXi, contain-
ing 5′ exon IA, exon IXi, and 3′ exon X, having a protein coding region
of 2892bp; (4) NFATC4-IB-IXL, containing 5′ exon IB, exon IXL, and 3′
exon X, having a protein coding region of 2745bp; (5) NFATC4-IB-IXS,
containing 5′ exon IB, exon IXS, and 3′ exon X, having a protein coding
region of 2421bp; (6) NFATC4-IB-IXi, containing 5′ exon IB, exon IXi,
and 3′ exon X, having a protein coding region of 2742bp; (7) NFATC4-
IC-IXL, containing 5′ exon IC, exon IXL, and 3′ exon X, having a protein
coding region of 2802bp; (8) NFATC4-IC-IXS, containing 5′ exon IC,
exon IXS, and 3′ exon X, having a protein coding region of 2478bp; (9)
NFATC4-IC-IXi, containing 5′ exon IC, exon IXi, and 3′ exon X, having a
protein coding region of 2799bp; (10) NFATC4-ID-IXL, containing 5′
exon ID, exon IXL, and 3′ exon X, having a protein coding region of
2706bp; (11) NFATC4-ID-IXS, containing 5′ exon ID, exon IXS, and 3′
exon X, having a protein coding region of 2382bp; (12) NFATC4-ID-IXi,
containing 5′ exon ID, exon IXi, and 3′ exon X, having a protein coding
region of 2703bp; (13) NFATC4-IE-IXL, containing 5′ exon IE, exon IXL,
and 3′ exon X, having a protein coding region of 2670bp; (14) NFATC4-
IE-IXS, containing 5′ exon IE, exon IXS, and 3′ exon X, having a protein
coding region of 2346bp; (15) NFATC4-IE-IXi, containing 5′ exon IE,
exon IXi, and 3′ exon X, having a protein coding region of 2667bp; (16)
NFATC4-IEi-IXL, containing 5′ exon IEi, exon IXL, and 3′ exon X, having
a protein coding region of 2496bp; (17) NFATC4-IEi-IXS, containing 5′
exon IEi, exon IXS, and 3′ exon X, having a protein coding region of
2172bp; (18) NFATC4-IEi-IXi, containing 5′ exon IEi, exon IXi, and 3′
exon X, having a protein coding region of 2493bp; (19) NFATC4-IV-IXL,
containing exon IV as the 5′ exon, exon IXL, and 3′ exon X, having a
protein coding region of 1311bp; (20) NFATC4-IV-IXS, containing exon
IV as the 5′ exon, exon IXS, and 3′ exon X, having a protein coding
region of 987bp; (21) NFATC4-IV-IXi, containing exon IV as the 5′ exon,
exon IXi, and 3′ exon X, having a protein coding region of 1308bp; (22)
NFATC4-VI-IXL, containing exon VI as the 5′ exon, exon IXL, and 3′ exon
X, having a protein coding region of 570bp; (23) NFATC4-VI-IXS,
containing exon VI as the 5′ exon, exon IXS, and 3′ exon X, having a
protein coding region of 246bp; and (24) NFATC4-VI-IXi, containing
exon VI as the 5′ exon, exon IX, and 3′ exon X, having a protein coding
region of 567bp (Supplementary Table 1).
Expression of mouse Nfatc4 exon I mRNA was detected in all
tissues analyzed, with higher levels in the lung, heart, testis, and
spleen (Fig. 2). During brain development, the highest levels were
observed at E13, the ﬁrst developmental stage analyzed, and the
expression decreased thereafter, reaching the lowest levels at
postnatal day 14 and remaining unchanged thereafter. In the adult
mouse brain the highest levels of Nfatc4 exon I transcripts were
detected in the thalamus and colliculi. Transcripts containing the
extended 5′ exon VI or VIi were evenly expressed in all the peripheral
tissues tested (Fig. 2). The highest expression levels of Nfatc4 exon IXL
and IXi transcripts were detected in the lung, heart, and muscle. In the
brain IXL transcript levels decreased during development, while IXi
transcripts were higher during postnatal development. In adult mouse
brain these transcripts were most strongly expressed in the colliculi,
midbrain, and cerebellum (Fig. 2).
In human, NFATC4 transcripts comprising 5′ exons IB, IC, ID, and VI
were expressed more widely than 5′ exon IA, IE, and IV transcripts
(Fig. 3). Exon IA transcriptswere detectedonly in the testis and prostate.
Exon IB and IC transcripts were both expressed in several tissues,
including the stomach, testis, kidney, trachea, adrenal gland, thyroid,
and cerebellum. Transcripts containing exon ID were expressed in
almost all tissues analyzed, with the highest levels in the small
intestine, uterus, testis, prostate, placenta, thyroid, and cerebellum. Low
levels of exon IE- and IEi-containing transcripts were seen only in the
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relatively high also in the heart and uterus. Expression levels of
transcripts containing exon VI as the 5′ exon were moderate in all
tissues tested (Fig. 3). The 3′ exon X-containing transcripts of NFATC4
were expressed according to the sum of the expression patterns of the
5′ exons. Highest levels were detected in the uterus, testis, placenta,
trachea, adrenal gland, thyroid, and cerebellum. In most tissues,
transcripts containing exon IXL were relatively more abundant than
transcripts containing exon IXS. Transcripts containing the 3′ exon IX
were expressed at low levels in the testis, kidney, and thymus. In the
brain, all the transcript types ofNFATC4, except exon IA transcripts,were
expressed in the cerebellum (Fig. 3). In addition, high levels of 5′ exon
ID, IV, and VI transcripts were detected in other brain regions: exon ID
mRNAs in the olfactory bulb, hippocampus, caudate nucleus, and optic
nerve; exon IV transcripts in the cerebral cortex, corpus callosum, and
hippocampus; and exon VI transcripts in the olfactory bulb and
cerebellum. Expression of exonX-containing transcripts, corresponding
to the sum of allNFATC4mRNAs, was detected in all brain regions, with
highest levels in the cerebellum, where exon IXL-containing transcripts
were the predominant ones (Fig. 3).Fig. 4. In situ hybridization analysis of Nfatc1, Nfatc2, Nfatc3, and Nfatc4 mRNA expression in
and G) and coronal sections at the level of thalamus (B, D, F, and H). The sections were hybrid
H). Gl, glomerular layer of olfactory bulb; GrO, granular layer of olfactory bulb; OB, olfac
hippocampus; Th, thalamus; Hth, hypothalamus; Mb, midbrain; Po, pons; Cb, cerebellum; MIn situ hybridization analyses of NFATC1, NFATC2, NFATC3, and NFATC4
expression in adult mouse brain and human hippocampus
Expression of NFAT mRNAs at the cellular level has not been
studied thoroughly by in situ hybridization before. Therefore we
analyzed the expression of NFAT mRNAs in adult mouse brain by in
situ hybridization. The hybridization probes for each NFATmRNAwere
constructed to recognize all of the major splice variants and therefore
were targeted to the conserved RHD coding region of NFAT mRNAs. To
distinguish different cell types, Nissl counterstaining of the tissue
sections, which allows one to distinguish the large and weakly stained
nuclei of neurons from the small and strongly stained nuclei of glial
cells, was used. All of the NFAT mRNAs were expressed in the neurons
of the brain, with speciﬁc patterns for each NFAT.
We observed similarities and differences in the expression patterns
of Nfatc1, Nfatc2, Nfatc3, and Nfatc4 (Figs. 4 and 5 and Supplementary
Fig. 3). In the olfactory system Nfatc1 was highly expressed in the
granular layer and glomerular cell layer and Nfatc2 in the mitral cell
layer (Figs. 4 and 5). A moderate signal was detected in the glomerular
and granular cell layer for Nfatc2 (Figs. 4A, 4C, 5A, and 5D). Nfatc3 andadult mouse brain. Dark-ﬁeld emulsion autoradiographs from sagittal sections (A, C, E,
ized with a probe for Nfatc1 (A and B), Nfatc2 (C and D), Nfatc3 (E and F), or Nfatc4 (G and
tory bulb; Mi, mitral layer of olfactory bulb; Ctx, cortex; Cpu, caudate putamen; Hc,
e, medulla; Am, amygdala; DG, dentate gyrus. Scale bars, 1 mm.
Fig. 5. In situ hybridization analysis of Nfatc1, Nfatc2, Nfatc3, and Nfatc4mRNA expression in adult mouse brain. Bright-ﬁeld higher magniﬁcation pictures of the olfactory bulb (A, D,
G, and J), cerebellum (B, E, H, and K), and choroid plexus (C, F, I, and L) are shown. Filled arrowheads denote some positive neurons, some negative neurons are marked with unﬁlled
arrowheads. The sections were hybridized with a probe for Nfatc1 (A, B, and C), Nfatc2 (D, E, and F), Nfatc3 (G, H, and I), or Nfatc4 (J, K, and L). Gl, glomerular cell layer of the olfactory
bulb; GrO, granular cells of the olfactory bulb; Mi, mitral cell layer, PC, Purkinje cells; GC, granular cells of the cerebellum; Neg, negative cell. Scale bar, 50 μm.
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layer (Figs. 4E, 4G, 5G, and 5J). In addition, Nfatc4was expressed in the
mitral cell layer (Figs. 4G and 5J).
In the cerebral cortex Nfatc2 mRNA expression was detected at
relatively high levels in the neurons of layers II–VI (Fig. 4C and
Supplementary Figs. 3A–D). The expression levels of other NFAT
family members in this brain region were below the detection limit of
our in situ hybridization method. Although all NFAT mRNAs were
detected in the hippocampal formation, there were differences in the
distribution and level of expression between different NFAT genes.
Nfatc2 showed a strong signal in the hippocampus, particularly in
the CA1–CA3 pyramidal layers, and slightly lower levels in the
granular layer of the dentate gyrus (Figs. 4C and D and Supplementary
Figs. 3B–D). Nfatc3 mRNA was moderately expressed only in the
granular layer of the dentate gyrus and was detected at low levels in
the CA1–CA3 pyramidal layers (Figs. 4E and F). Nfatc1 and Nfatc4
mRNAs were expressed at evenly low levels in both the CA1–CA3
pyramidal cells and the dentate gyrus granular cells (Figs. 4A and B).In the basal ganglia, evenly distributed moderate signal was detected
for Nfatc2 in the caudate putamen, ventral pallidum, accumbens, and
septum (Fig. 4C and Supplementary Fig. 3A), whereas Nfatc1mRNAwas
expressed at moderate levels only in the region of bed nucleus of stria
terminalis (data not shown). Nfatc3 and Nfatc4 mRNAs were not
expressed signiﬁcantly in these brain structures (Figs. 4E and G). In the
thalamus, hypothalamus, and midbrain Nfatc2 mRNA was widely
expressed at high or moderate levels in most of the nuclei (Figs. 4C and
D and Supplementary Figs. 3B and C). In contrast, signal forNfatc1, Nfatc3,
andNfatc4wasbarelydetectable in these structures (Figs. 4A, B, andE–H).
In the cerebellum all NFAT transcriptswere expressed (Figs. 4 and 5).
Nfatc1 and Nfatc4 were moderately expressed only in the granular
neurons (Figs. 4A, 4G, 5B, and 5K), whereas Nfatc2 and Nfatc3 were
expressed in the granular cell layer and also in the Purkinje cell layer
(Figs. 4C, 4E, 5E, and 5H). In the granular layer cells the signal for Nfatc2
andNfatc3was relatively stronger than that forNfatc1 andNfatc4. In the
pons andmedulla only Nfatc2 showedmoderate expression all over the
region (Fig. 4C and Supplementary Figs. 3E and F).
Fig. 6. In situ hybridization analysis of NFATC1, NFATC2, NFATC3, and NFATC4 mRNA expression in adult human hippocampus. Dark-ﬁeld emulsion autoradiographs from coronal
sections at the level of hippocampus. GrDG, granular cell layer of the dentate gyrus; PyCA3, CA3 pyramidal cells; hf, hippocampal ﬁssure. Scale bar, 1 mm.
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expressed at high levels and Nfatc3 and Nfatc4 at moderate levels
(Figs. 5C, F, I, and L).
In the human hippocampus all four NFATs were expressed. For all
NFATs stronger signal was detected in the granular layer of the dentate
gyrus, in the pyramidal neurons of CA3 region, and in the hippocampal
ﬁssure (Fig. 6).
Discussion
The aim of this studywas to characterize the structures, alternative
splicing, and expression of the NFAT genes in human and in mouse.
Our results on the structures of the NFAT genes are in agreement with
previous data from other groups [28,29,33,42,43] and also add
important new data about the complex splicing and expression of
this gene family. NFAT genes encode proteins that are very similar in
their central region, which encodes the Rel homology domain, but are
clearly variable in their N- and C-terminal parts due to the less
conserved 5′ and 3′ regions of the paralogs of the genes, which differ
signiﬁcantly in their protein-coding potencies. Here we show that the
NFAT genes are even more diverse in the 5′ and 3′ regions than
previously described. All NFAT genes in human and mouse have
multiple alternatively used 5′ exons: according to our data human and
mouse NFATC1 and NFATC2 and mouse Nfatc3 and Nfatc4 have two
alternative 5′ exons; human NFATC3 has six and NFATC4 has seven
alternative 5′ exons. We show that usage of 3′-terminal exons is also
complex: human and mouse NFATC1 and NFATC3 genes contain two
and the mouse Nfatc2 contains three alternative 3′ exons. Human
NFATC2 and both human and mouse NFATC4 have one 3′ exon. In
addition, alternative splicing is used for all NFAT genes and in
combination with the usage of alternative 5′ and 3′ exons this could
theoretically lead to 8 different protein isoforms of NFATC1, 6 different
isoforms of both NFATC2 and NFATC3, and 24 different isoforms of
NFATC4 in human.
The alternative 5′ exons of NFATC1 have been described before
[24,29,44,45] and the results of our bioinformatic and expression
studies conﬁrm that the NFATC1 gene has two alternative 5′ exons in
both mouse and human. Also, our expression analyses are consistent
with studies showing NFATC1 expression predominantly in the
immune system [23–26,46]. For NFATC2 only one 5′ exon had been
previously described [41]. Herewe have identiﬁed and characterized a
novel alternative 5′ exon for both human and mouse NFATC2. Weshow that in human the previously known NFATC2 5′ exon, exon IB,
and the novel alternative 5′ exon, named here exon IA, are expressed
at similar levels in most of the tissues, except in the heart, where exon
IB-containing mRNAs are the predominant transcripts. In mouse
though, exon IA is used predominantly in the brain and exon IB both in
the brain and in nonneural tissues. In addition to the novel NFATC2 5′
exon we describe a novel splice variant of exon II that is conserved in
human and mouse and results in a short form of exon II, named IIS
here. Usage of the short variant of exon II is the predominant splicing
event in mouse for transcripts starting with exon IA. However, in
human, exon IIS transcripts of NFATC2 are barely detectable. NFATC2
exon IIS-containing transcripts encode proteins without the N-
terminal CaN binding site and serine-rich region. The functions of
such isoforms are yet to be elucidated.
We have shown here that human NFATC3 and NFATC4 contain six
and ﬁve 5′ exons, respectively. The human NFATC3 exon IB and NFATC4
exon ID are the only 5′ exons homologous to a 5′ exon inmouse Nfatc3
and Nfatc4, respectively. These homologous exons are the only 5′
exons that have been previously described for NFATC3 and NFATC4
[23]. In human NFATC3 and NFATC4 the 5′ exons are located very close
to each other in the 5′ ends of the genes. The close placement of the
exons leaves open the possibility that they compile one exon with
multiple transcription start sites. However, bioinformatic and PCR
analyses showed that the 5′ sequences of both human NFATC3 and
NFATC4 transcripts are not overlapping and use distinct splice donor
sites, indicating that they are derived from different exons. In addition,
there is an alternative transcription start site in human NFATC4
located upstream of exon IV. Usage of this transcription start site
generates protein isoforms that are similar to the NFATC3 isoforms
encoded by transcripts with the novel 5′ exons IA, IC, and ID of
NFATC3, which yield NFAT isoforms without the whole regulatory
domain. The function of these proteins is unclear. However, since we
found generation of such isoforms for both NFATC3 and NFATC4 in
human, these isoforms could be important in functions yet undeﬁned.
Another interesting observation about the putative N-termini of the
human NFATC3 and NFATC4 is that although exon IB of human NFATC3
and exons IA, IB, IC, and ID of human NFATC4 encode N-termini that
are different comparing the whole sequence, they clearly contain a
conserved stretch of 12 amino acids—[E/D]EL[E/D]FKLVFGE[E/D]
(Supplementary Fig. 1). The N-termini of the NFAT proteins have
previously been shown to contain TADs [17]. We suggest that the TADs
of the NFAT proteins contain important motifs that probably function
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different gene regulation activities.
The 3′ regions of NFAT genes are also diverse due to alternative
splicing and usage of alternative 3′ exons. For example, in human,
exon IX ofNFATC1 can be alternatively spliced in threeways, leading to
transcripts lacking exon IX (ΔIX), with a long variant of exon IX (IXL) or
with a short variant of exon IX (IXS). ΔXI transcripts have not been
described before. Similar to the N-termini of NFAT proteins, there is a
conserved motif (LDQ[T/L]YLDD(VN)E[I/L]I[R/D]) in the C-terminal
sequences that locates to the C-terminal TAD of the NFATC1 and
NFATC2 proteins [17] (Supplementary Fig. 2). This sequence is present
only in the NFATC1 isoform NFATC1-IXL, whereas it is present in all
human NFATC2 isoforms (Supplementary Fig. 2). In addition, by
bioinformatics we found that this conserved motif contains a putative
NES (Supplementary Fig. 2). Hence the isoforms lacking the sequence
may act differently compared to the isoforms containing the TAD/NES.
Our expression analysis of NFATC1 showed that splice variants with
exon IXS, encoding protein isoforms lacking the conserved motif, are
the most abundantly expressed transcripts.
Alternative 3′ exons of NFAT genes are used in a species-speciﬁc
manner. For example, for the mouse Nfatc2, exon VIIa has been shown
to be an alternative 3′ exon and transcripts that include this exon are
expressed speciﬁcally in neurons and encode a constitutively active
isoform [33]. Our expression analysis conﬁrmed that this Nfatc2
transcript, named here Nfatc2IB-IIS-VIIa, is expressed in the mouse
brain. However, in human, the homolog of this Nfatc2 transcript is not
expressed. Our analysis showed that similar species-speciﬁc differ-
ences are present also for human and mouse NFATC3. In human, and
not in mouse, exon IX is used as an alternative 3′ exon. Transcripts
including this exon encode the human-speciﬁc NFATC3 protein
isoform containing a C-terminal TAD with a different transactivation
potential compared to other NFATC3 C-terminal TADs [28]. In this
study we have shown that this transcript is expressed in all human
tissues analyzed. Furthermore, we show that Nfatc3 transcripts using
exon IV as the 3′ exon encoding a protein isoform lacking most of the
Rel homology domain are expressed in mouse, in most of the tissues
analyzed, and not in human. These data combined show that different
NFAT C-termini could potentially have functionally unique character-
istics, emphasizing that although NFAT proteins may have redundancy
in their functions, as can be concluded from knockout studies [47,48],
the speciﬁc functions of different NFAT isoforms could have an impact
on Ca2+-dependent gene expression in different tissues and species
depending on the isoform expressed. Species-speciﬁc splicing and
usage of alternative 5′ exons have also been shown to regulate other
genes, for example, splicing of the p53 tumor suppressor gene [49]
and usage of 5′ exons of the transcription factor NR5A1 [50].
In previous studies only NFATC4 expression has been characterized
in more detail in some regions of adult nervous system and cultured
primary neurons [21,35,36,38,39,51,52]. However, there is evidence
that NFATC2 and NFATC3 might also have important functions in the
nervous system. Mice with the combination of Nfatc2, Nfatc3, and
Nfatc4 mutations have a complete defect of midline crossing of the
commissural neurons in response to netrins and neurons from these
mice are unable to respond to neurotrophins [47], whereas NFAT
single-knockout mice have lesser neuronal defects [2,19]. In addition,
there is evidence that NFATC2 and NFATC3 are expressed in some
regions of the brain—in the hypothalamus and olfactory bulb
[24,31,32]. To date there are no indications of NFATC1 expression in
the brain. To ﬁnd out which of the NFAT genes are expressed in the
adult brain and in which cells they are expressed we analyzed
expression of NFAT mRNAs in adult mouse brain using in situ
hybridization. Our results showed that Nfatc2 is broadly expressed
throughout the adult mouse brain and is the predominantly expressed
NFAT in the mouse brain. The highest Nfatc2 mRNA levels were
detected in the pyramidal cell layer of the CA1–CA3 regions of the
hippocampus, in the Purkinje and granule cell layers of thecerebellum, olfactory bulb, hypothalamus, and thalamus. Surprisingly,
we found that Nfatc1 is also expressed in mouse brain, having the
highest expression levels in the granular and glomerular cell layers of
the olfactory bulb. Moderate expressionwas seen also in the cerebellar
granule cells. This suggests that NFATC1may have important functions
in the brain in addition to the functions in the tissues described earlier
by others [24,26,52]. Before this study NFATC3 expression in the brain
had been demonstrated only in the hypothalamus and striatum and in
certain cell lines of neuronal origin [31,35]. Here we describe NFATC3
expression in the cerebellar granule cells and in Purkinje cells and, to a
lesser extent, in the granule cells of the dentate gyrus and olfactory
bulb. Therefore, our ﬁndings are consistent with the knockout studies
showing that both NFATC2 and NFATC3 contribute to the development
and function of the nervous system [47].
Several studies have shown that NFATC4 is expressed in the brain,
giving the notion that NFATC4 might be the most abundant NFAT
expressed in the nervous system. Expression has been shown in the
adult rat hippocampus using RT-PCR and in situ hybridization and in
the adult mouse hippocampus using RT-PCR [21], in cultured rat
striatal cells using Western blot analysis [35] and in the adult mouse
striatumusing immunohistochemistry [51], in adultmouse dorsal root
ganglion and spinal cord using in situ hybridization [36], in cultured
rat cerebellar granule cells using immunocytochemistry [38], in adult
mouse hippocampus using immunohistochemistry [39], and in
cultured rat hippocampal neurons using immunocytochemistry [53].
However, we detected only low levels of Nfatc4 expression in the
brain. To ensure credibility we repeated the assay twice using two
different hybridization probes. We show here that Nfatc4 is indeed
expressed in the brain but at lower levels compared to the other
NFATs. Moderate expression was detected only in the cerebellar,
olfactory bulb, and dentate gyrus granule cells and in themitral cells of
the olfactory bulb. On the other hand, according to our PCR analysis of
NFAT expression during mouse brain development, Nfatc4 was more
abundantly expressed in the earlier stages of development and the
levels were decreased during later stages. Therefore, Nfatc4 function
might be especially important in the developing brain. Surprisingly,
our PCR results showed that NFATC4 is relatively highly expressed in
the human brain, indicating again that NFAT signaling could have
species-speciﬁc features. Moreover, in situ hybridization analysis
showed that in the adult human brain all NFAT genes are expressed in
the CA1–CA3 pyramidal neurons and dentate gyrus granule cells.
Notably, in the human brain all the NFATs, among other regions,
were expressed in the corpus callosum and optic nerve—regions of the
brain containing mainly neuronal projections and glial cells. By in situ
hybridization, we found that the majority of the signal in the mouse
brain accumulated in certain neuronal populations, although for all
NFATs, very low signal was detected all over the brain, including glial
cells. Thus, it is possible that in addition to neurons, NFAT genes are
also expressed in glial cells. In the human hippocampus all NFATswere
expressed in the CA3 pyramidal neurons and dentate gyrus granular
cell layer and also in the hippocampal ﬁssure, which further supports
the possibility that NFATgenes are expressed in both neurons and glial
cells.
In conclusion, the results of this study provide comprehensive data
about the structure, splicing pattern, and expression of NFAT genes in
human and mouse, providing useful information for future studies
aiming to elucidate the functions of different NFAT isoforms.
Materials and methods
Structure, expression analysis, and cloning of the NFAT genes
Human NFAT gene structures and human and mouse NFAT mRNAs
were identiﬁed by analyzing genomic, mRNA, and EST databases using
bioinformatics tools (http://www.ncbi.nlm.nih.gov and http://genome.
ucsc.edu). All homology searches were performed using various BLAST
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software at http://www.cbs.dtu.dk/services/NetNES/ site and NLSswere
predicted using software at http://wolfpsort.org/ site. Rel homology and
serine-rich sequence motifs were predicted using the software at the
http://expasy.org/prosite/ site. Based on the sequence information
acquired, primers were designed to analyze the expression of human
and mouse NFAT mRNAs and to construct plasmids for mouse and
humanNFAT riboprobe generation (Supplementary Table 2). Total RNAs
from various human and mouse brain regions and mouse tissues were
puriﬁed with RNAwiz (Ambion, USA) as recommended by the
manufacturer and treated with DNase using a DNA-free kit (Ambion).
Human RNAs from different tissues were obtained from BD Biosciences
(USA). First-strand cDNAs were synthesized from 5 μg of total RNAwith
Superscript III reverse transcriptase (Invitrogen, USA) as recommended
by the manufacturer. Fire polymerase, Hot-Fire polymerase (Solis
Biodyne, Estonia), or the GC-Rich PCR System (Roche, Switzerland)
wasused in PCR for expression analyses and riboprobe template plasmid
construction, all according to the manufacturer’s instructions. An
annealing temperature of 57°Cwas used for all combinations of primers.
Cycle numbers were optimized so that the PCR products were analyzed
in the exponential phaseof thePCR.Dependingon theprimers used, 30–
40 cycles of PCR were performed. PCR fragments were resolved by
agarose gel electrophoresis. PCR with primers speciﬁc for the ubiqui-
tously expressed glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
25 cycles, was performed as a control to determine the amount of
human template cDNA in different PCRs. For normalizing the amount of
mouse template cDNA and the amount of template cDNA in the panel of
human brain regions, a 30-cycle PCR with primers speciﬁc for the
ubiquitously expressed hypoxanthine guanine phosphoribosyl transfer-
ase (HPRT) was performed. All PCRswere performed in a volume of 10 μl
containing 1/80 of the reverse transcription reaction product as a
template. All PCR products were veriﬁed by sequencing.
In situ hybridization
For both human and mouse the in situ hybridization probes were
generated as follows. The NFAT riboprobe fragments were selected to
cover the parts of the NFAT mRNAs that are present in all mainly
expressed splice variants of NFATC1, NFATC2, NFATC3, or NFATC4. DNA
fragments ampliﬁed for NFAT riboprobe generation (Supplementary
Table 2) were excised from the gel and cloned into pSC-A PCR cloning
vector (Stratagene, USA). The mouse NFAT plasmids were linearized
adjacent to the5′ ends of the cloned fragments. Thehybridizationprobes
for mouse were 519, 524, 436, and 831 nt in length for Nfatc1, Nfatc2,
Nfatc3, and Nfatc4, respectively. For Nfatc4 the template for the second
assaywasgenerated bydigestion at theBglII site inside the clonedNfatc4
sequence and the length of the probe was 456 bp. For human in situ
hybridization the plasmids with NFATC1, NFATC2, NFAT3, and NFATC4
were linearized with Eco45III, NcoI, NcoI, or HindIII restriction enzyme
inside the cloned sequences, respectively. The lengths of the resulting
riboprobeswere 697 nt forNFATC1, 615 nt forNFATC2, 876 nt forNFATC3,
and 816nt forNFATC4. cRNAprobeswere synthesizedwith aMAXIScript
in vitro transcription kit (Ambion), using [α-35S]UTP (Amersham
Biosciences) for labeling, according to the manufacturer’s instructions.
Serial sagittal and coronal sections (20 μm) from fresh-frozen adultmale
Black 6 mouse brains and coronal sections (16 μm) from fresh-frozen
adult male human hippocampus were subjected to in situ hybridization
using a protocol described elsewhere by Timmusk et al. [54]. Emulsion-
dipped sections were developed after 7 weeks using D-19 developer
(Eastman Kodak, USA), ﬁxed (sodium ﬁxer; Kodak), and counterstained
with hematoxylin (Shandon, USA).
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